20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over...
Hence then, the article about skyrizi risankizumab and rinvoq upadacitinib data highlight long term clinical and endoscopic outcomes across inflammatory bowel disease ibd at uegw 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 )
Also on site :
- Dow Jones Futures: S&P 500, Nasdaq Break Key Levels As CoreWeave, Dell Dive; Tesla, SpaceX, Meta Loom
- ServiceNow CFO says leaders working 14 hours and getting 4 hours of sleep set a ‘terrible example’ for their employees
- The Hollywood Reporter, Animation Is Film Festival Partner on Live Animation Roundtable With Bill Hader, Travis Knight, More